EFSA: New Assessment on Vitamin B6 and Neurological Risks

Background

The European Food Safety Authority (EFSA) has conducted a comprehensive reassessment of vitamin B6 (pyridoxine) safety. This was triggered by several reports of peripheral neuropathy in consumers of high-dose vitamin B6 supplements.

Key Findings

• New Maximum Level: EFSA proposes a new UL (Tolerable Upper Intake Level) of 12.5 mg/day for adults (previously 25 mg/day)
• Risk Groups: Special caution for long-term use exceeding 6 months
• Symptoms: Numbness, tingling, coordination disorders

Impact for Manufacturers

1. Review existing formulations
2. Adjust dosage recommendations
3. Update warning labels
4. Possible national implementation in 2025

Recommendations

• Check your products with our compliance tool
• Prepare formula adjustments
• Inform your distribution partners early